Bengaluru, January 26, 2026: The merger between Aster DM Healthcare Limited, and Quality Care
India Ltd, one of the largest merger announcements in the healthcare industry has now received an
order from the Hon’ble National Company Law Tribunal (NCLT), Hyderabad Bench to convene the
shareholders and unsecured trade creditors meeting for approval of the merger. The meeting will be
fixed for a date between February 27, 2026 and March 13, 2026. The merger transaction is already in
receipt of approvals from Competition Commission of India (CCI) and ‘No Objection’ letters from the
Stock Exchanges. The company expects to complete the merger process by Q1 FY27, subject to
receipt of all regulatory approvals and completion of other conditions precedents.
The merged entity ‘Aster DM Quality Care’ will be promoted by Aster Promoters and Blackstone and
brings together the strengths of two leading healthcare providers with a common vision of
expanding access to high-quality medical care across the country.
Dr. Azad Moopen, Founder & Chairman, Aster DM Healthcare, said, “We are pleased with the
significant progress achieved in the merger process and are confident of shareholders/ unsecured
creditors approval as well as pursuant to the NCLT order. We remain committed to working toward a
speedy completion of the merger and look forward to making it effective by Q1 FY2026-27. Looking
ahead, our focus will be on executing a disciplined integration strategy that leverages the
complementary networks, clinical expertise, and operational strengths of Aster and Quality Care.
The merger provides a strong platform to scale efficiently, enhance clinical excellence, and
accelerate innovation, enabling us to build a more resilient and future-ready healthcare organization
that delivers improved access and outcomes for patients across the country.”
The merged entity ‘Aster DM Quality Care Limited’ will have a combined portfolio of four leading
brands: Aster DM, CARE Hospitals, KIMSHEALTH and Evercare. As of September 30, 2025, the
combined bed strength of Aster and QCIL stands over 10,360 beds with bed strength of Aster at
5,195+ beds and QCIL at 5,165+ respectively. Looking ahead, the merged entity aspires to increase
bed capacity to around 14,715+ beds over the coming years. With the combined scale, the merged
entity will also be well-positioned to explore investments in advanced medical technologies and
digital health platforms – driving innovation and creating a more integrated, seamless patient
experience.